title: Effect of cytomegalovirus-induced immune response, self antigen-induced immune response, and microbial translocation on chronic immune activation in successfully treated HIV type 1-infected patients: the ANRS CO3 Aquitaine Cohort.
abstract: We evaluated the impact of cytomegalovirus (CMV)-induced immune responses, autoimmune-induced immune responses, and microbial translocation on immune activation in 191 human immunodeficiency virus type 1-infected patients from the ANRS CO3 Aquitaine Cohort. All enrolled subjects had achieved long-term virological suppression during receipt of combination antiretroviral therapy (cART). HLA-DR(+)/CD38(+) expression was 16.8% among CD8(+) T cells. Independent of age, CD4(+) T-cell count, 16S ribosomal DNA load, and regulatory T-cell count, positive results of Quantiferon CMV analysis (P = .02), positive results of CMV-pp65 enzyme-linked immunosorbent spot analysis (P = .01), positive results of CMV-pp65-specific CD8(+) T-cell analysis (P = .05), and CMV seropositivity (P = .01) were associated with a higher percentage of CD8+ T cells that expressed HLA-DR+/CD38+. Autoimmune response and microbial translocation were not associated with immune activation. Therefore, the CMV-induced immune response seems to be associated with chronic immune activation in cART recipients with sustained virological suppression.
authors.affiliation: University Bordeaux, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, France. linda.wittkop@isped.u-bordeaux2.fr
authors.forename: Linda
authors.initials: L
authors.lastname: Wittkop
authors.forename: Juliette
authors.initials: J
authors.lastname: Bitard
authors.forename: Estibaliz
authors.initials: E
authors.lastname: Lazaro
authors.forename: Didier
authors.initials: D
authors.lastname: Neau
authors.forename: Fabrice
authors.initials: F
authors.lastname: Bonnet
authors.forename: Patrick
authors.initials: P
authors.lastname: Mercie
authors.forename: Michel
authors.initials: M
authors.lastname: Dupon
authors.forename: Mojgan
authors.initials: M
authors.lastname: Hessamfar
authors.forename: Michel
authors.initials: M
authors.lastname: Ventura
authors.forename: Denis
authors.initials: D
authors.lastname: Malvy
authors.forename: François
authors.initials: F
authors.lastname: Dabis
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Pellegrin
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Moreau
authors.forename: Rodolphe
authors.initials: R
authors.lastname: Thiébaut
authors.forename: Isabelle
authors.initials: I
authors.lastname: Pellegrin
mesh_terms: D023241:Antiretroviral Therapy, Highly Active; D015551:Autoimmunity; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000276:immunology; D005260:Female; D005602:France; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D006684:HLA-DR Antigens / Q000378:metabolism; D006801:Humans; D008213:Lymphocyte Activation / Q000276:immunology*; D008297:Male; D010750:Phosphoproteins / Q000276:immunology*; D019562:Viral Load; D014763:Viral Matrix Proteins / Q000276:immunology*
chemical_list: D006684:HLA-DR Antigens; D010750:Phosphoproteins; D014763:Viral Matrix Proteins; C065418:cytomegalovirus matrix protein 65kDa